Merck & Co. launched a tender offer on January 14, 2003 for the remaining 49% of Banyu Pharmaceutical it did not already own, valued at approximately $1.5 billion at 1,400 yen per share. The transaction closed on March 6, 2003, after which Banyu was delisted.